Therapy Areas: Oncology
QIAGEN launches QIAsymphony Connect and showcases new precision oncology advances at AMP 2025
10 November 2025 - Netherlands-based holding company QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) announced on Monday that it unveiled QIAsymphony Connect, the next generation of its autom...
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL
10 November 2025 - Biotechnology company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) announced on Monday that it has received FDA clearance to proceed with its confirmatory Phase 3 TELLOMAK ...
AN2 Therapeutics partners with GSK to develop boron-based TB therapies; Secures Gates Foundation funding
10 November 2025 - Biopharmaceutical company AN2 Therapeutics Inc (Nasdaq: ANTX) revealed on Monday that it has entered into a research collaboration with biopharmaceutical firm GSK to advance boron-b...
Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests
10 November 2025 - Cancer screening and diagnostic tests provider Exact Sciences Corp (NASDAQ: EXAS) on Monday announced the expiration of the Hart-Scott-Rodino Antitrust Act waiting period for its pr...
Akeso reveals preclinical research data for novel antagonistic monoclonal antibody aimed at IL-1RAP (AK135)
10 November 2025 - Akeso Inc (HKEX: 9926.HK), a China-based biopharmaceutical company, on Friday reported the preclinical research data for its novel antagonistic monoclonal antibody aimed at IL-1RAP,...
Boehringer Ingelheim receives Commissioner's National Priority Voucher for HERNEXEOS (zongertinib tablets)
10 November 2025 - Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zonge...